Factors Affecting Drug Response

Why This Matters

When you're tested on pharmacology, you're not just being asked to recall drug names. You're being evaluated on whether you understand why the same drug can work perfectly in one patient and cause serious harm in another. The factors affecting drug response sit at the intersection of pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body). Mastering these concepts means understanding absorption, distribution, metabolism, and excretion (ADME) and how patient-specific variables alter each step.

Drug response depends on dozens of variables: genetics, organ function, body composition, timing, and even what the patient ate for breakfast. Exam questions will ask you to predict how changing one variable affects the outcome, or to identify which factor explains an unexpected drug response. Don't just memorize that "elderly patients need lower doses." Know why (reduced hepatic blood flow, decreased renal clearance, altered body composition). That mechanistic understanding is what separates strong exam performance from guesswork.

---

Pharmacokinetic Modifiers: How the Body Handles Drugs

These factors alter how drugs are absorbed, distributed, metabolized, or excreted, changing the concentration of active drug that reaches its target. The core principle: anything that affects ADME will shift drug levels, potentially causing toxicity or therapeutic failure.

Age

Neonates and elderly patients sit at opposite ends of the same problem: immature or declining organ function.

• Neonates have underdeveloped hepatic enzymes (especially CYP450s and glucuronidation pathways), reduced renal filtration, and higher body water percentage. This means drugs stay active longer and distribute differently than in adults.
• Elderly patients show reduced liver mass and hepatic blood flow (about a 30–40% decline by age 65), which slows metabolism of drugs cleared by the liver.
• Volume of distribution shifts with age as total body water decreases and body fat increases in older adults. Hydrophilic drugs become more concentrated (higher peak levels), while lipophilic drugs accumulate in fat and have prolonged effects.
• Renal clearance declines predictably with age. The Cockcroft-Gault equation estimates this decline, making it essential for dosing renally cleared drugs like aminoglycosides, vancomycin, and digoxin.

Body Weight and Composition

• Volume of distribution ($V_d$) scales with body size. Larger patients may need higher loading doses to achieve therapeutic concentrations.
• Obesity alters pharmacokinetics unpredictably because lipophilic drugs (like benzodiazepines) accumulate in fat tissue, extending their duration of action, while hydrophilic drugs (like aminoglycosides) don't distribute proportionally into fat.
• Lean body mass, not total body weight, determines clearance for many drugs. Dosing an obese patient by total body weight for a hydrophilic drug can cause toxicity because the drug concentrates in a relatively smaller water compartment.

Liver and Kidney Function

• Hepatic impairment reduces first-pass metabolism. Drugs normally cleared extensively by the liver (like propranolol or morphine) reach systemic circulation at much higher concentrations than expected.
• Renal impairment prolongs half-life of drugs eliminated by the kidneys, requiring dose reduction or extended dosing intervals. Failing to adjust for renal function is one of the most common causes of drug toxicity in clinical practice.
• Child-Pugh score (for hepatic impairment) and creatinine clearance (for renal impairment) are the clinical tools used to guide these dosing adjustments.

Dosage and Route of Administration

• Bioavailability varies dramatically by route. IV administration provides 100% bioavailability, while oral drugs must survive the GI tract and first-pass metabolism before reaching systemic circulation.
• First-pass effect can eliminate over 90% of some oral drugs (nitroglycerin is a classic example) before they reach the bloodstream. This is why certain medications require sublingual, transdermal, or parenteral routes.
• Onset and duration depend on route. Sublingual and inhaled routes bypass first-pass metabolism and provide rapid onset, which is why nitroglycerin is given sublingually for acute angina and albuterol is inhaled for acute bronchospasm.

---

Genetic and Biological Variation

Individual differences in enzyme activity, receptor sensitivity, and physiological state create predictable patterns of altered drug response. Pharmacogenomics explains why "standard doses" fail in certain populations.

Genetic Factors (Pharmacogenomics)

• CYP450 polymorphisms create poor, intermediate, extensive (normal), and ultra-rapid metabolizers. A poor metabolizer of codeine gets no pain relief because they can't convert codeine to its active form (morphine) via CYP2D6. An ultra-rapid metabolizer converts codeine too quickly, producing dangerously high morphine levels.
• Drug transporter variants (like P-glycoprotein and OATP) affect how much drug enters target tissues or gets pumped back into the gut lumen, altering effective drug concentrations even when plasma levels look normal.
• HLA variants predict severe drug reactions. HLA-B5701 screening before prescribing abacavir (an HIV drug) prevents life-threatening hypersensitivity. HLA-B1502 screening before carbamazepine prevents Stevens-Johnson syndrome in at-risk populations.

Sex Differences

• Women generally have higher body fat percentage and lower $V_d$ for water-soluble drugs, which can lead to higher plasma concentrations at the same dose. Zolpidem dosing, for example, was reduced for women after post-market data showed prolonged next-morning impairment.
• Hormonal fluctuations affect CYP enzyme activity. Estrogen inhibits certain CYP pathways while progesterone may induce others, meaning drug metabolism can shift across the menstrual cycle and during oral contraceptive use.
• QT prolongation risk is higher in women, making sex a consideration when prescribing drugs that affect cardiac conduction (like certain antiarrhythmics and fluoroquinolones).

Individual Variations in Drug Metabolism

Even without identified genetic variants, patients can show up to 10-fold differences in drug clearance for the same medication. Age, sex, genetics, and disease all converge to create each patient's unique metabolic profile.

Therapeutic drug monitoring (TDM) directly measures drug levels in the blood. It's used when variability is high and the therapeutic window is narrow, as with drugs like lithium, phenytoin, vancomycin, and aminoglycosides.

---

Drug-Drug and Drug-Environment Interactions

Other medications, food, toxins, and timing can dramatically alter drug response through predictable mechanisms. These are highly testable because they're preventable with proper clinical awareness.

Drug Interactions

• Enzyme induction (e.g., rifampin, carbamazepine, phenytoin) accelerates metabolism of co-administered drugs by increasing CYP450 enzyme production. This can cause therapeutic failure. A classic example: rifampin reduces the effectiveness of oral contraceptives, potentially leading to unintended pregnancy.
• Enzyme inhibition (e.g., ketoconazole, erythromycin, ritonavir) slows metabolism, increasing drug levels and toxicity risk. Induction takes days to weeks (new enzyme synthesis is required), while inhibition can occur within hours.
• Competition for plasma protein binding can transiently increase free (active) drug concentration. This effect is often overstated in textbooks because the body usually compensates by increasing clearance of the now-unbound drug.

Diet and Nutrition

• Grapefruit juice inhibits intestinal CYP3A4, and a single glass can increase levels of statins or calcium channel blockers several-fold. The effect can last up to 72 hours because grapefruit irreversibly inactivates the enzyme, and new enzyme must be synthesized.
• High-fat meals increase absorption of lipophilic drugs (like griseofulvin) while also delaying gastric emptying, which slows overall absorption rate.
• Vitamin K-rich foods (leafy greens, broccoli) antagonize warfarin by providing substrate for clotting factor synthesis. Patients on warfarin don't need to avoid these foods entirely, but they need to keep intake consistent so the warfarin dose stays calibrated.

Environmental Factors

• Smoking induces CYP1A2. Smokers require higher doses of theophylline, clozapine, and olanzapine. When a patient quits smoking, the induction fades over about a week, and drug levels can rise suddenly, causing toxicity if doses aren't reduced.
• Occupational exposures to solvents or heavy metals can alter hepatic enzyme activity unpredictably.
• Adherence barriers (cost, access, health literacy, complex regimens) affect whether prescribed doses actually reach the patient. A drug can't work if it isn't taken.

---

Temporal and Adaptive Factors

Drug response changes over time due to biological rhythms, repeated exposure, and physiological adaptations. These factors explain why the same dose stops working or why timing matters.

Circadian Rhythms (Chronopharmacology)

• Hepatic enzyme activity fluctuates over 24 hours. Some drugs are metabolized faster in the morning than at night.
• Blood pressure follows a circadian pattern (dipping at night, surging in the early morning), making evening dosing of certain antihypertensives more effective at preventing morning cardiovascular events.
• Corticosteroid timing mimics natural cortisol release. Morning dosing aligns with the body's peak cortisol production, which reduces suppression of the hypothalamic-pituitary-adrenal (HPA) axis.

Tolerance and Dependence

These are distinct but related concepts:

• Pharmacodynamic tolerance occurs when receptors downregulate or desensitize after repeated agonist exposure. The drug is still reaching the receptor, but the receptor responds less. This requires dose escalation to maintain the same effect (common with opioids and benzodiazepines).
• Pharmacokinetic tolerance results from enzyme induction. The body increases production of metabolizing enzymes, so the drug is broken down faster with repeated dosing. Less drug reaches the target.
• Physical dependence reflects neuroadaptation. The body adjusts its baseline signaling to account for the drug's constant presence. Abrupt discontinuation unmasks these compensatory changes, causing withdrawal symptoms.

Pregnancy and Lactation

Pregnancy changes nearly every pharmacokinetic parameter:

• Increased plasma volume (up to 50%) and cardiac output dilute drug concentrations and accelerate renal clearance. Glomerular filtration rate increases by about 50%, meaning renally cleared drugs are eliminated faster.
• Placental transfer follows lipophilicity rules. Small, lipophilic, un-ionized, non-protein-bound drugs cross readily to the fetus.
• FDA pregnancy categories (A, B, C, D, X) have been replaced by narrative labeling (the Pregnancy and Lactation Labeling Rule, or PLLR) that provides more detailed risk-benefit information. Many drugs still lack adequate human data.

---

Psychological and Subjective Factors

The mind-body connection influences measurable drug outcomes through mechanisms that are increasingly well understood. These factors are especially relevant in clinical trials and pain management.

Placebo Effect

• Placebo responses involve real neurobiological changes, including endorphin release, dopamine signaling, and measurable changes in brain activation patterns on functional MRI.
• Expectation and conditioning drive the magnitude of the placebo response. Patients who expect relief show greater response, and prior positive experiences with treatment amplify the effect.
• Clinical trial design must control for placebo through blinding and randomization to isolate true drug effects. This is why the gold standard is the randomized, double-blind, placebo-controlled trial.

Disease States

Disease doesn't just create the need for drugs; it changes how drugs behave in the body.

• Pathophysiology alters pharmacokinetics. Heart failure reduces hepatic blood flow (decreasing metabolism of flow-dependent drugs like lidocaine). Burns increase $V_d$ through capillary leak and fluid shifts.
• Receptor expression changes in disease. Beta-receptor downregulation in chronic heart failure reduces the response to beta-agonists, which is why beta-agonists aren't first-line heart failure therapy.
• Polypharmacy in chronic disease multiplies interaction risk and complicates attribution of adverse effects. A patient on 10 medications has 45 possible pairwise drug interactions.

---

Quick Reference Table

---

Self-Check Questions

1. A patient stabilized on warfarin suddenly shows elevated INR after starting a new medication. Which two factors could explain this, and what mechanism do they share?

2. Compare and contrast how age and obesity affect volume of distribution. Which types of drugs are most affected by each?

3. An ultra-rapid CYP2D6 metabolizer is prescribed codeine for pain. Predict the clinical outcome and explain the pharmacogenomic principle involved.

4. Why might a drug requiring hepatic metabolism need increased dosing during pregnancy despite the goal of minimizing fetal exposure?

5. A patient reports that their blood pressure medication "stopped working" after they quit smoking. Which factor explains this, and what's the underlying mechanism?